{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-23-000045","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.051085+00:00","generated_at":"2026-06-12T07:05:06.147139+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lexicon reports Q2 net loss $44.9M; FDA-approved INPEFA launched, LX9211 advancing","bullets":["FDA approved INPEFA (sotagliflozin) for heart failure across full LVEF range; U.S. launch completed within 30 days.","LX9211 moving into late-stage development for DPNP; Phase 2b dose optimization study starts Q3 2023.","Q2 2023 net loss of $44.9M ($0.22 per share) vs $24.6M ($0.16) in Q2 2022.","SG&A expenses rose to $30.0M from $10.7M due to commercial launch preparations; R&D $14.5M vs $13.4M.","Cash and investments $256.7M as of June 30, 2023, up from $138.4M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-23-000045","json":"https://secwatch.observer/filing/0001062822-23-000045.json","markdown":"https://secwatch.observer/filing/0001062822-23-000045.md","text":"https://secwatch.observer/filing/0001062822-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000045/0001062822-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000045/lxrx-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:05:06.147139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}